Healthcare ETFs to Buy as JNJ Slips 6% Despite Q3 Earnings Beat

What happened: Johnson & Johnson $JNJ shares initially fell nearly 6% on Oct. 13 after third-quarter 2026 results, as its MedTech segment missed expectations despite beating estimates on the top and bottom lines. Key numbers: Adjusted EPS $2.59, beat consensus by 2.4%. Why it matters: Management cited geopolitical headwinds including the Middle East conflict and pricing pressure in China, and modestly raised full-year 2026 revenue and earnings guidance. The article suggests healthcare ETFs with high $JNJ exposure as a way to capture its momentum while reducing single-stock risk. Market: +1.9% today ($258.61), +26.1% YTD, 0.1x vol — as of 14:17 UTC

Johnson & Johnson $JNJ shares initially fell nearly 6% on Oct. 13 after third-quarter 2026 results, as its MedTech segment missed expectations despite beating estimates on the top and bottom lines.

Management cited geopolitical headwinds including the Middle East conflict and pricing pressure in China, and modestly raised full-year 2026 revenue and earnings guidance. The article suggests healthcare ETFs with high $JNJ exposure as a way to capture its momentum while reducing single-stock risk. Market: +1.9% today ($258.61), +26.1% YTD, 0.1x vol — as of 14:17 UTC